A previous study has shown that Trx neutralizes the intracellular toxic oxidants produced by cisplatin leading to the development of drug resistance (Sasada et al., 1996), and that drug-resistant cancer cells are more sensitive to inhibitors of the Trx system (Bjorkhem-Bergman et al., 2002). Here, TXN is linked to cancer.